Influenza is one of the fastest-changing vaccine-preventable diseases and has a significant impact on people and health systems across the globe. The World Health Organization (WHO) estimates that seasonal flu infects 1 billion people annually, causing severe illness in 3–5 million and 290,000–650,000 respiratory deaths.* As one of the world’s largest influenza vaccine providers, CSL Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness. With state-of-theart production facilities in the U.S., the U.K. and Australia, CSL Seqirus utilises egg, cell and adjuvant technologies to offer a broad portfolio of differentiated influenza vaccines in more than 20 countries around the world. 114m seasonal flu doses distributed globally 232m people protected in pandemic agreements 40k deaths prevented globally 355k hospitalisations prevented globally Advancing Public Health Protection for a Changing World | Introduction | For Patients | For Science | For Society | Looking Forward *Source: World Health Organization: www.who.int/news-room/fact-sheets/detail/influenza-(seasonal); last accessed 28 September 2026. CSL IMPACT REPORT 2026 | 17
RkJQdWJsaXNoZXIy MjE2NDg3